文献速递泌尿男性生殖肿瘤

单核苷酸多态性特征对局限性肾细胞癌复发的预测价值:回顾性分析及多中心验证研究

Predictive value of single-nucleotide polymorphism signature for recurrence in localised renal cell carcinoma: a retrospective analysis and multicentre validation study.
PubMed 文献 · Lancet Oncol · 2019-03-14

本研究基于44个复发相关单核苷酸多态性(SNP)开发了六-SNP分类器,用于预测局限性透明细胞肾细胞癌术后复发。训练集227例,内部测试集226例,独立验证集428例,TCGA集441例。分类器在三个验证集中均能精确预测无复发生存(HR 5.32、5.39、4.62,均p<0.0001),且不受肿瘤内异质性影响。

要点

  • 六-SNP分类器在内部测试集、独立验证集和TCGA集中预测无复发生存的HR分别为5.32、5.39、4.62,均p<0.0001。
  • 分类器预测准确性不受肿瘤内异质性影响,训练集三个区域5年AUC分别为0.749、0.734、0.736。
  • 分类器联合临床病理因素构建的列线图5年AUC为0.811(95%CI 0.756-0.861),显著高于各单一变量。

核心结论

  • 六-SNP分类器可作为实用可靠的预测工具,补充现有分期系统预测局限性肾细胞癌术后复发,可能帮助医生制定更明智的辅助治疗决策。
  • 肿瘤内异质性似乎不影响六-SNP分类器作为复发可靠预测工具的准确性。
  • 该分类器有潜力指导不同复发风险患者的治疗决策。

研究设计与样本

  • 回顾性分析及多中心验证研究,训练集为中山大学227例局限性透明细胞肾细胞癌患者的石蜡包埋标本。
  • 通过LASSO Cox回归基于SNP状态与无复发生存关联开发六-SNP分类器。
  • 在内部测试集(n=226)、独立验证集(中国多中心研究,2004年1月1日至2012年12月31日三家医院治疗的428例患者)和TCGA集(美国1998至2010年间因局限性透明细胞肾细胞癌接受切除的441例回顾性识别患者)中验证。
  • 主要结局为无复发生存,次要结局为总生存。

主要发现

  • 内部测试集206例有完整SNP信息的病例中48例(23%)存在肿瘤内异质性,但分类器在训练集三个不同区域的预测准确性相似(5年AUC:区域1为0.749 [95% CI 0.660-0.826],区域2为0.734 [0.651-0.814],区域3为0.736 [0.649-0.824])。
  • 六-SNP分类器在三个验证集中精确预测无复发生存(内部测试集HR 5.32 [95% CI 2.81-10.07],独立验证集HR 5.39 [3.38-8.59],TCGA集HR 4.62 [2.48-8.61];均p<0.0001),且独立于患者年龄、性别、肿瘤分期、分级或坏死。
  • 分类器与临床病理风险因素(肿瘤分期、分级和坏死)联合构建的列线图预测准确性显著高于各单一变量(5年AUC 0.811 [95% CI 0.756-0.861])。

关键数值与推荐

  • 六-SNP分类器在内部测试集预测无复发生存的HR为5.32(95% CI 2.81-10.07),p<0.0001。
  • 六-SNP分类器在独立验证集预测无复发生存的HR为5.39(95% CI 3.38-8.59),p<0.0001。
  • 六-SNP分类器在TCGA集预测无复发生存的HR为4.62(95% CI 2.48-8.61),p<0.0001。
  • 列线图5年AUC为0.811(95% CI 0.756-0.861),显著高于各单一变量。

临床怎么用

  • 作者认为六-SNP分类器可作为实用可靠的预测工具,补充现有分期系统预测局限性肾细胞癌术后复发。
  • 作者认为该分类器可能帮助医生制定更明智的辅助治疗决策。
  • 作者认为该分类器有潜力指导不同复发风险患者的治疗决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Identification of high-risk localised renal cell carcinoma is key for the selection of patients for adjuvant treatment who are at truly higher risk of reccurrence. We developed a classifier based on single-nucleotide polymorphisms (SNPs) to improve the predictive accuracy for renal cell carcinoma recurrence and investigated whether intratumour heterogeneity affected the precision of the classifier. METHODS: In this retrospective analysis and multicentre validation study, we used paraffin-embedded specimens from the training set of 227 patients from Sun Yat-sen University (Guangzhou, Guangdong, China) with localised clear cell renal cell carcinoma to examine 44 potential recurrence-associated SNPs, which were identified by exploratory bioinformatics analyses of a genome-wide association study from The Cancer Genome Atlas (TCGA) Kidney Renal Clear Cell Carcinoma (KIRC) dataset (n=114, 906 600 SNPs). We developed a six-SNP-based classifier by use of LASSO Cox regression, based on the association between SNP status and patients' recurrence-free survival. Intratumour heterogeneity was investigated from two other regions within the same tumours in the training set. The six-SNP-based classifier was validated in the internal testing set (n=226), the independent validation set (Chinese multicentre study; 428 patients treated between Jan 1, 2004 and Dec 31, 2012, at three hospitals in China), and TCGA set (441 retrospectively identified patients who underwent resection between 1998 and 2010 for localised clear cell renal cell carcinoma in the USA). The main outcome was recurrence-free survival; the secondary outcome was overall survival. FINDINGS: Although intratumour heterogeneity was found in 48 (23%) of 206 cases in the internal testing set with complete SNP information, the predictive accuracy of the six-SNP-based classifier was similar in the three different regions of the training set (areas under the curve [AUC] at 5 years: 0·749 [95% CI 0·660-0·826] in region 1, 0·734 [0·651-0·814] in region 2, and 0·736 [0·649-0·824] in region 3). The six-SNP-based classifier precisely predicted recurrence-free survival of patients in three validation sets (hazard ratio [HR] 5·32 [95% CI 2·81-10·07] in the internal testing set, 5·39 [3·38-8·59] in the independent validation set, and 4·62 [2·48-8·61] in the TCGA set; all p<0·0001), independently of patient age or sex and tumour stage, grade, or necrosis. The classifier and the clinicopathological risk factors (tumour stage, grade, and necrosis) were combined to construct a nomogram, which had a predictive accuracy significantly higher than that of each variable alone (AUC at 5 years 0·811 [95% CI 0·756-0·861]). INTERPRETATION: Our six-SNP-based classifier could be a practical and reliable predictor that can complement the existing staging system for prediction of localised renal cell carcinoma recurrence after surgery, which might enable physicians to make more informed treatment decisions about adjuvant therapy. Intratumour heterogeneity does not seem to hamper the accuracy of the six-SNP-based classifier as a reliable predictor of recurrence. The classifier has the potential to guide treatment decisions for patients at differing risks of recurrence. FUNDING: National Key Research and Development Program of China, National Natural Science Foundation of China, Guangdong Provincial Science and Technology Foundation of China, and Guangzhou Science and Technology Foundation of China.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Wei JH, Feng ZH, Cao Y, et al. Predictive value of single-nucleotide polymorphism signature for recurrence in localised renal cell carcinoma: a retrospective analysis and multicentre validation study. Lancet Oncol. 2019. PMID: 30880070. doi:10.1016/S1470-2045(18)30932-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。